Key Takeaways:
Bio-Rad Laboratories Inc. (NYSE: BIO) reported first-quarter adjusted earnings of $1.89 per share, missing the Zacks Consensus Estimate of $2.77 and falling below the $2.54 earned in the same period a year ago.
"The conflict [in the Middle East] substantially reduced Q1 2026 revenues and will be a significant headwind for revenue and margin for full year 2026," Jon DiVincenzo, President and Chief Operating Officer at Bio-Rad, said in a statement.
The significant earnings miss sent a bearish signal to investors, reflecting challenges in academic and diagnostic markets. Shares have declined nearly 4 percent since the start of the year, though they closed at $299.45 Thursday ahead of the report.
The Hercules, California-based company posted a net loss of $527.1 million, or $19.55 per share, for the quarter. This compares to a profit in the first quarter of the previous year. Revenue for the period was $592.1 million. The company did not disclose its revenue consensus estimate.
Management cited geopolitical headwinds as a primary factor, noting the Middle East has been one of its fastest-growing markets, representing over 9 percent of its diagnostics segment. The life science division saw flat net sales as constrained academic budgets in the Americas impacted demand.
Despite the headwinds, Bio-Rad's biopharma business showed early signs of stabilization, and its ddPCR instrument revenue grew 24 percent over the prior year, an encouraging sign for future consumable sales. Investors will be watching for continued execution of the company's strategic initiatives to offset the macroeconomic pressures in the upcoming quarters.
This article is for informational purposes only and does not constitute investment advice.
